Cure8 research brief
Persistent perineal sinus is a common and impactful complication after proctectomy for Crohn disease that can prolong recovery and require further care. Knowing rates of healing and risk factors can help patients and clinicians set expectations and consider strategies to lower risk.
Adult patients with Crohn disease facing proctectomy, clinicians who perform or manage postoperative care for IBD surgery, and patients with perianal disease or prior multiple therapies.
This study looked back at all proctectomies for Crohn disease at one tertiary center over 30 years to measure how often the perineal wound fails to heal (PPS) and which factors were linked to it. PPS was defined as a perineal wound not healed by 6 months after surgery.
Healing rates were about 81% at 6 months and 94% at 12 months, and median healing time was under 2 months overall.
The analysis found younger patients and those who had omentoplasty were more likely to have PPS before adjusting for year of surgery; after adjustment, older age predicted faster healing, and having had three or more prior therapy lines showed a possible protective trend but was not statistically significant.
The authors conclude most patients do eventually heal and suggest controlling systemic inflammation could help reduce PPS risk.
This is a retrospective, single-center cohort study spanning 1993–2023; associations may be affected by changes in surgical practice and medical therapy over time. The report is based on an abstract-level extraction from the journal Annals of Surgery; it summarizes observed associations but does not prove causation.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declare that there is no conflict of interest regarding the publication of this paper.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
